Impairment of nucleotide metabolism by iron-chelating deferoxamine.
The effect of deferoxamine on nucleotide metabolism in HL-60 leukemic cells was studied to explore the mechanism of its antiproliferation activity. It was found that in intact cells deferoxamine markedly inhibited the ribonucleotide reduction and incorporation of bases (adenine, hypoxanthine), ribonucleosides (inosine, guanosine) and deoxyribonucleosides (thymidine, deoxyadenosine, deoxyguanosine) into nucleic acids. Although deferoxamine did not inhibit thymidine and uridine incorporation into free nucleotides, inhibition of hypoxanthine and adenine incorporation into nucleotides as well as inhibition of nucleotide biosynthesis de novo was found. Nucleotide catabolism, protein synthesis, and intracellular levels of ribonucleotides were not affected significantly by deferoxamine. These results showed that deferoxamine selectively affects several specific reactions of nucleotide metabolism. Inhibition of ribonucleotide reduction, inhibition of ribonucleotide and deoxyribonucleotide incorporation into nucleic acids, as well as inhibition of purine biosynthesis, may alter significantly cellular physiology and, therefore, contribute significantly to the antiproliferative activity of deferoxamine.
D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003676:Deferoxamine / Q000494:pharmacology*; D003864:Depression, Chemical; D006801:Humans; D007501:Iron / Q000502:physiology; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000473:pathology; D008297:Male; D009705:Nucleosides / Q000378:metabolism; D009711:Nucleotides / Q000378:metabolism*; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism
D009705:Nucleosides; D009711:Nucleotides; D011687:Purines; D011743:Pyrimidines; D007501:Iron; D003676:Deferoxamine